FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lamothe Jeffrey G. 		2. Issuer Name and Ticker or Trading Symbol

Aptevo Therapeutics Inc. [ APVO ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP, CFO and Treasurer
(Last)          (First)          (Middle)

2401 4TH AVENUE, SUITE 1050 		3. Date of Earliest Transaction (MM/DD/YYYY)

8/3/2016
(Street)

SEATTLE, WA 98121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

8/5/2016 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                  0   (1) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit     (2) 8/3/2016     A      50680         (3)   (3) Common Stock   50680   $0   104994   (4) D    
Stock Option (right to buy)   (5)   (6)                    (7)   (8) Common Stock   108532     108532   D    

Explanation of Responses:
( 1)  This report has been amended to reflect that the reporting person does not now, nor has he ever, held any shares of the Issuer's common stock.
( 2)  Each RSU represents the right of the reporting person to receive one share of common stock of the Issuer.
( 3)  This report has been amended to reflect that the RSUs will vest in two equal installments on February 3, 2017 and February 3, 2018.
( 4)  This report has been amended to reflect the 35,451 RSUs that were originally issued by Emergent BioSolutions, Inc. ("Emergent") and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed by the Issuer under its Converted Equity Awards Incentive Plan.
( 5)  This report has been amended to include the stock options that were originally issued by Emergent and, as a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, were adjusted and assumed under the Issuer's Converted Equity Awards Incentive Plan.
( 6)  37,736 of the Reporting Person's stock options are exercisable at an exercise price of $2.47 per share; 26,996 of the Reporting Person's stock options are exercisable at an exercise price of $2.55 per share; and 43,800 of the Reporting Person's stock options are exercisable at an exercise price $2.97.
( 7)  37,736 of the Reporting Person's stock options fully vest on March 10, 2017; 26,996 of the Reporting Person's stock options vest as follows: 13,504 on March 10, 2017 and 13,492 on March 10, 2018; and 43,800 of the Reporting Person's stock options vest in three equal installments on March 1, 2017, March 1, 2018 and March 1, 2019.
( 8)  37,736 of the Reporting Person's stock options expire on March 10, 2021; 26,996 of the Reporting Person's stock options expire on March 9, 2022; and 43,800 of the Reporting Person's stock options expire on February 28, 2026.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Lamothe Jeffrey G.
2401 4TH AVENUE, SUITE 1050
SEATTLE, WA 98121

SVP, CFO and Treasurer

Signatures
/s/ Benjamin J. Stein, attorney-in-fact 9/27/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aptevo Therapeutics Charts.
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aptevo Therapeutics Charts.